Lipum (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced its participation in the following upcoming events.

Stora Aktiedagarna | 5 March | Stockholm, Sweden

Redeye Investor Forum Online | 7 March | Digital

Biostock Health and Wealth | 11-15 March | Digital

BIO-Europe Spring | 18-20 March | Barcelona, Spain

LSX World Congress | 29-30 April | London, UK

“I am looking forward to these meetings. The first part of the clinical phase 1 study has been completed with positive results and the industry meetings provide great opportunities to present our progress. " says CEO Ola Sandborgh

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum to participate in following upcoming

Lipum to participate in following upcoming